skip to Main Content

DPP-4 Inhibitors Linked to Risk for Pancreatitis, Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Use of dipeptidyl peptidase-4 inhibitors (DPP-4is) is associated with an increased risk for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to study results published in Diabetes Care.

DPP-4is are incretin-based agents known to have effects on pancreatic function. Researchers aimed to investigate the risk for pancreatitis and pancreatic cancer associated with the use of DPP-4is in patients newly diagnosed with type 2 diabetes from the Korean National Health Insurance Service–Health Screening Cohort database. Read more . . . 

Back To Top